|Systematic (IUPAC) name|
|Pregnancy cat.||C (US)|
|Legal status||℞-only (US)|
|Metabolism||Hepatic (CYP3A4, with minor contributions from CYP2A6, CYP1A2)|
|Excretion||Urine (58%), faeces (39%)|
|Mol. mass||460.500 g/mol|
Apremilast (brand name Otezla) is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells. It has anti-inflammatory activity.
Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis. It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.
- "Otezla (aprelimast) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 28 March 2014.
- "Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results" (Press release). Celgene Corporation. 13 January 2014. Retrieved 2014-01-21.
- FDA approves Otezla to treat psoriatic arthritis
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|